| Literature DB >> 36004354 |
Jingyi Ren1, Guangqing Tan1, Xinyi Ren1, Weiyu Lu1, Qiling Peng2, Jing Tang3,4, Yingxiong Wang2,3, Biao Xie5, Meijiao Wang1,3.
Abstract
Polycystic ovary syndrome (PCOS) exerts negative effects on females of childbearing age. It is important to identify more suitable models for fundamental research on PCOS. We evaluated animal models from a novel perspective with the aim of helping researchers select the best model for PCOS. RNA sequencing was performed to investigate the mRNA expression profiles in the ovarian tissues of mice with dehydroepiandrosterone (DHEA) plus high-fat diet (HFD)-induced PCOS. Meanwhile, 14 datasets were obtained from the Gene Expression Omnibus (GEO), including eight studies on humans, three on rats and three on mice, and genes associated with PCOS were obtained from the PCOSKB website. We compared the consistency of each animal model and human PCOS in terms of DEGs and pathway enrichment analysis results. There were 239 DEGs shared between prenatally androgenized (PNA) mice and PCOS patients. Moreover, 1113 genes associated with PCOS from the PCOSKB website were identified among the DEGs of PNA mice. A total of 134 GO and KEGG pathways were shared between PNA mice and PCOS patients. These findings suggest that the PNA mouse model is the best animal model to simulate PCOS.Entities:
Keywords: RNA sequencing (RNA-seq); animal model; bioinformatics; dehydroepiandrosterone (DHEA); differentially expressed genes (DEG); polycystic ovary syndrome (PCOS)
Mesh:
Substances:
Year: 2022 PMID: 36004354 PMCID: PMC9393894 DOI: 10.3389/fendo.2022.950105
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 6.055
Figure 1The workflow used in this study is illustrated.
Details of microarray and RNA-seq datasets.
| Accession ID | Platform | Platform ID | Number of patients | Symbol (N/P) | Organism | Modelling method |
|---|---|---|---|---|---|---|
| GSE1615 | Affymetrix HG-U133A | GPL96 | 9 | 4/5 | Homo sapiens | NA |
| GSE5850 | Affymetrix HG-U133A 2.0 | GPL570 | 12 | 6/6 | Homo sapiens | NA |
| GSE10946 | Affymetrix HG-U133A 2.0 | GPL570 | 23 | 11/12 | Homo sapiens | NA |
| GSE34526 | Affymetrix HG-U133A 2.0 | GPL570 | 10 | 3/7 | Homo sapiens | NA |
| GSE98595 | Affymetrix HG-1_0-st | GPL6244 | 8 | 3/5 | Homo sapiens | NA |
| GSE102293 | Affymetrix HG-U133A 2.0 | GPL570 | 6 | 4/2 | Homo sapiens | NA |
| GSE137684 | Agilent SurePrint G3 GE 8x60K | GPL17077 | 12 | 4/8 | Homo sapiens | NA |
| GSE168404 | Illumina HiSeq 2500 | GPL16791 | 10 | 5/5 | Homo sapiens | NA |
| GSE108499 | RiboArray Rat mRNA | GPL24411 | 12 | 3/3 | Rattus norvegicus | TBT |
| 3/3 | BPA | |||||
| 3/3 | TBT plus BPA | |||||
| GSE83220 | Illumina HiSeq 2500 | GPL18694 | 4 | 2/2 | Rattus norvegicus | HFHS |
| GSE59456 | Affymetrix Rat 230 2.0 | GPL1355 | 8 | 4/4 | Rattus norvegicus | DHT |
| GSE156895 | Illumina HiSeq 2000 | GPL13112 | 5 | 2/3 | Mus musculus | PNA |
| GSE103056 | Affymetrix Mouse 430 2.0 | GPL1261 | 2 | 1/1 | Mus musculus | PNA |
| GSE171431 | Affymetrix MTA-1_0 | GPL20258 | 6 | 3/3 | Mus musculus | DHT |
| Our data | Illumina NovaSeq | – | 6 | 3/3 | Mus musculus | DHEA plus HFD |
TBT, tributyltin; BPA, bisphenol A; DHT, dihydrotestosterone; PNA, prenatally androgenized; DHEA, dehydroepiandrosterone; HFD, high fat diet; HFHS, high fat high sugar; NA, not available.
Figure 2PCA score plots for classifying samples from different datasets. (A) Human datasets before batch effect removal. (B) Human datasets after batch effect removal by the EB method. (C) Rat datasets before batch effect removal. (D) Rat datasets after batch effect removal by the EB method. (E) Mouse datasets before batch effect removal. (F) Mouse datasets after batch effect removal by the EB method.
Information about the eight groups PCOS animal models.
| Method | Specie | Treatment time | Estrus cycle | CL | AF | Atr F | CF | FSH | LH | T | E2 | Body weight | Ovary body index | Abnormal metabolism | Reference |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| SD rats | 16d | irregular | ↓ | ↓ | ↑ | ↑ | NS | NA | NA | NA | NA | ↓ | lipid metabolism disorder | ( |
| Wistar dams | 30d | irregular | NA | NA | ↑ | ↑ | NA | NA | ↑ | ↓ | ↑ | ↓ | abnormal lipid accumulation | ( | |
|
| SD rats | 16d | irregular | ↓ | ↓ | ↑ | ↑ | NA | NA | NA | NA | NA | ↓ | lipid metabolism disorder | ( |
| SD rats | 10d | irregular | ↓ | ↓ | ↑ | ↑ | NS | ↑ | ↑ | ↑ | NS | ↓ | NA | ( | |
|
| SD rats | 16d | irregular | ↓ | ↓ | ↑ | ↑ | NA | ↑ | ↑ | NA | NA | ↓ | lipid metabolism disorder | ( |
|
| SD rats | 11w | irregular | ↓ | NA | ↑ | ↑ | NS | NS | NA | NA | ↑ | NS | insulin resistance | ( |
| SD rats | 14w | irregular | ↓ | NA | NS | ↑ | NA | ↓ | ↑ | ↓ | ↑ | NS | insulin resistance | ( | |
|
| C57BL/6J mice | 70d | irregular | ↓ | ↓ | ↑ | ↑ | ↓ | ↑ | NS | ↑ | ↑ | NS | hypercholesterolemia | ( |
| SD rats | 90d | irregular | ↓ | ↓ | ↓ | ↑ | ↑ | ↑ | ↓ | ↓ | ↑ | ↓ | insulin resistance | ( | |
|
| ICR mice | gestational days 16–18 | irregular | ↓ | ↑ | ↑ | ↑ | NA | ↑ | ↑ | ↑ | ↑ | ↑ | abnormal folate one-carbon metabolism | ( |
| SD rats | gestational days 16–19 | irregular | ↓ | ↓ | ↑ | ↑ | NA | ↑ | ↑ | ↑ | NS | NS | insulin resistance | ( | |
|
| SD rats | 20d | irregular | ↓ | ↓ | NA | ↑ | NS | ↑ | ↑ | ↑ | ↑ | NS | lipid metabolism disorder | ( |
| C57BL/6J mice | 20d | irregular | ↓ | NA | ↑ | ↑ | ↑ | ↑ | ↑ | NS | ↑ | NS | lipid metabolic disorders | ( |
SD, Sprague-Dawley; CL, corpora lutea; AF, antral follicles; Atr F, atretic follicles; CF, cystic follicles; FSH, follicle-stimulating hormone; LH, luteinizing hormone; E2, estradiol; T, testosterone; NA, not available; NS, no significance ; ↓, reduce;↑, increase.
Figure 3Venn diagram showing the intersection of DEGs (including up-regulated genes and down-regulated genes) between the PCOS animal modeland patients. (A) DEGs of the TBT-induced PCOS rat model. (B) DEGs of the BPA-induced PCOS rat model. (C) DEGs of the TBT plus BPAinduced PCOS rat model. (D) DEGs of the HFHS-induced PCOS rat model. (E) DEGs of the DHT-induced PCOS rat model. (F) DEGs of the PNA PCOS mouse model. (G) DEGs of the DHT-induced PCOS mouse model. (H) DEGs of the DHEA plus HFD-induced PCOS mouse model.
Figure 4Differential mRNA expression of the top five DEGs shared between PNA mice and PCOS patients. (A) The gene level of Atg2a. (B) The gene level of Tapbp. (C) The gene level of Tagln. (D) The gene level of P4ha1. (E) The gene level of Amz2.
Figure 5Venn diagram showing the intersection of PCOS animal models and genes from PCOSKB. (A) DEGs of the TBT-induced PCOS rat model. (B) DEGs of the BPA-induced PCOS rat model. (C) DEGs of the TBT plus BPA-induced PCOS rat model. (D) DEGs of the HFHS-induced PCOS rat model. (E) DEGs of the DHT-induced PCOS rat model. (F) DEGs of the PNA PCOS mouse model. (G) DEGs of the DHT-induced PCOS mouse model. (H) DEGs of the DHEA plus HFD-induced PCOS mouse model.
Figure 6Venn diagram showing the intersection of pathway enrichment analyzes between PCOS animal models and patients. (A) GO and KEGG terms enriched in the TBT-induced PCOS rat model. (B) GO and KEGG terms enriched in the BPA-induced PCOS rat model. (C) GO and KEGG terms enriched in the TBT plus BPA-induced PCOS rat model. (D) GO and KEGG terms enriched in the HFHS-induced PCOS rat model. (E) GO and KEGG terms enriched in the DHT-induced PCOS rat model. (F) GO and KEGG terms enriched in the PNA PCOS mouse model. (G) GO and KEGG terms enriched in the DHT-induced PCOS mouse model. (H) GO and KEGG terms enriched in the DHEA plus HFD-induced PCOS mouse mod.
Figure 7The top ten enriched pathways shared between PCOS patients and PNA mice. (A) Chord diagram. (B) Bubble diagram.
Figure 8PPI network analysis of DEGs in PNA mice. (A) A PPI network with 211 nodes and 492 edges was constructed using Cytoscape software. (B) The top module results of MCODE PPI analysis. (C) The ten genes with the greatest linkage were selected for treatment as hub genes.